Search for "amino group" in Full Text gives 405 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2020, 16, 1022–1050, doi:10.3762/bjoc.16.91
Graphical Abstract
Figure 1: Categories I–V of fluorinated phenylalanines.
Scheme 1: Synthesis of fluorinated phenylalanines via Jackson’s method.
Scheme 2: Synthesis of all-cis-tetrafluorocyclohexylphenylalanines.
Scheme 3: Synthesis of ʟ-4-[sulfono(difluoromethyl)]phenylalanine (nPt: neopentyl, TCE: trichloroethyl).
Scheme 4: Synthesis of ʟ-4-[sulfono(difluoromethyl)]phenylalanine derivatives 17.
Scheme 5: Synthesis of fluorinated Phe analogues from Cbz-protected aminomalonates.
Scheme 6: Synthesis of tetrafluorophenylalanine analogues via the 3-methyl-4-imidazolidinone auxiliary 25.
Scheme 7: Synthesis of tetrafluoro-Phe derivatives via chiral auxiliary 31.
Scheme 8: Synthesis of 2,5-difluoro-Phe and 2,4,5-trifluoro-Phe via Schöllkopf reagent 34.
Scheme 9: Synthesis of 2-fluoro- and 2,6-difluoro Fmoc-Phe derivatives starting from chiral auxiliary 39.
Scheme 10: Synthesis of 2-[18F]FPhe via chiral auxiliary 43.
Scheme 11: Synthesis of FPhe 49a via photooxidative cyanation.
Scheme 12: Synthesis of FPhe derivatives via Erlenmeyer azalactone synthesis.
Scheme 13: Synthesis of (R)- and (S)-2,5-difluoro Phe via the azalactone method.
Scheme 14: Synthesis of 3-bromo-4-fluoro-(S)-Phe (65).
Scheme 15: Synthesis of [18F]FPhe via radiofluorination of phenylalanine with [18F]F2 or [18F]AcOF.
Scheme 16: Synthesis of 4-borono-2-[18F]FPhe.
Scheme 17: Synthesis of protected 4-[18F]FPhe via arylstannane derivatives.
Scheme 18: Synthesis of FPhe derivatives via intermediate imine formation.
Scheme 19: Synthesis of FPhe derivatives via Knoevenagel condensation.
Scheme 20: Synthesis of FPhe derivatives 88a,b from aspartic acid derivatives.
Scheme 21: Synthesis of 2-(2-fluoroethyl)phenylalanine derivatives 93 and 95.
Scheme 22: Synthesis of FPhe derivatives via Zn2+ complexes.
Scheme 23: Synthesis of FPhe derivatives via Ni2+ complexes.
Scheme 24: Synthesis of 3,4,5-trifluorophenylalanine hydrochloride (109).
Scheme 25: Synthesis of FPhe derivatives via phenylalanine aminomutase (PAM).
Scheme 26: Synthesis of (R)-2,5-difluorophenylalanine 115.
Scheme 27: Synthesis of β-fluorophenylalanine via 2-amino-1,3-diol derivatives.
Scheme 28: Synthesis of β-fluorophenylalanine derivatives via the oxazolidinone chiral auxiliary 122.
Scheme 29: Synthesis of β-fluorophenylalanine from pyruvate hemiketal 130.
Scheme 30: Synthesis of β-fluorophenylalanine (136) via fluorination of β-hydroxyphenylalanine (137).
Scheme 31: Synthesis of β-fluorophenylalanine from aziridine derivatives.
Scheme 32: Synthesis of β-fluorophenylalanine 136 via direct fluorination of pyruvate esters.
Scheme 33: Synthesis of β-fluorophenylalanine via fluorination of ethyl 3-phenylpyruvate enol using DAST.
Scheme 34: Synthesis of β-fluorophenylalanine derivatives using photosensitizer TCB.
Scheme 35: Synthesis of β-fluorophenylalanine derivatives using Selectflour and dibenzosuberenone.
Scheme 36: Synthesis of protected β-fluorophenylalanine via aziridinium intermediate 150.
Scheme 37: Synthesis of β-fluorophenylalanine derivatives via fluorination of α-hydroxy-β-aminophenylalanine d...
Scheme 38: Synthesis of β-fluorophenylalanine derivatives from α- or β-hydroxy esters 152a and 155.
Scheme 39: Synthesis of a series of β-fluoro-Phe derivatives via Pd-catalyzed direct fluorination of β-methyle...
Scheme 40: Synthesis of series of β-fluorinated Phe derivatives using quinoline-based ligand 162 in the Pd-cat...
Scheme 41: Synthesis of β,β-difluorophenylalanine derivatives from 2,2-difluoroacetaldehyde derivatives 164a,b....
Scheme 42: Synthesis of β,β-difluorophenylalanine derivatives via an imine chiral auxiliary.
Scheme 43: Synthesis of α-fluorophenylalanine derivatives via direct fluorination of protected Phe 174.
Figure 2: Structures of PET radiotracers of 18FPhe derivatives.
Figure 3: Structures of melfufen (179) and melphalan (180) anticancer drugs.
Figure 4: Structure of gastrazole (JB95008, 181), a CCK2 receptor antagonist.
Figure 5: Dual CCK1/CCK2 antagonist 182.
Figure 6: Structure of sitagliptin (183), an antidiabetic drug.
Figure 7: Structure of retaglpitin (184) and antidiabetic drug.
Figure 8: Structure of evogliptin (185), an antidiabetic drug.
Figure 9: Structure of LY2497282 (186) a DPP-4 inhibitor for the treatment of type II diabetes.
Figure 10: Structure of ulimorelin (187).
Figure 11: Structure of GLP1R (188).
Figure 12: Structures of Nav1.7 blockers 189 and 190.
Beilstein J. Org. Chem. 2020, 16, 966–973, doi:10.3762/bjoc.16.85
Graphical Abstract
Figure 1: (R)-MeO-MOP and our ligands.
Scheme 1: Asymmetric Suzuki–Miyaura coupling. Reaction conditions: 1 equiv N-aryl-bromoaryl compounds, 2 equi...
Scheme 2: Asymmetric Suzuki–Miyaura coupling. Reaction conditions: 1 equiv of bromoaryl compounds, 2 equiv of...
Scheme 3: Gram-scale reaction.
Scheme 4: Based on our analysis and speculation, a possible intermediate structure is proposed [65,66].
Scheme 5: Method A for the synthesis of amide substrates.
Scheme 6: Method B for the synthesis of amide substrates.
Beilstein J. Org. Chem. 2020, 16, 917–955, doi:10.3762/bjoc.16.83
Graphical Abstract
Figure 1: Chemical structures of the porphyrinoids and their absorption spectra: in bold are highlighted the ...
Figure 2: Photophysical and photochemical processes (Por = porphyrin). Adapted from [12,18].
Figure 3: Main dual photocatalysts and their oxidative/reductive excited state potentials, including porphyri...
Scheme 1: Photoredox alkylation of aldehydes with diazo acetates using porphyrins and a Ru complex. aUsing a ...
Scheme 2: Proposed mechanism for the alkylation of aldehydes with diazo acetates in the presence of TPP.
Scheme 3: Arylation of heteroarenes with aryldiazonium salts using TPFPP as photocatalyst, and corresponding ...
Scheme 4: A) Scope with different aryldiazonium salts and enol acetates. B) Photocatalytic cycles and compari...
Scheme 5: Photoarylation of isopropenyl acetate A) Comparison between batch and continuous-flow approaches an...
Scheme 6: Dehalogenation induced by red light using thiaporphyrin (STPP).
Scheme 7: Applications of NiTPP as both photoreductant and photooxidant.
Scheme 8: Proposed mechanism for obtaining tetrahydroquinolines by reductive quenching.
Scheme 9: Selenylation and thiolation of anilines.
Scheme 10: NiTPP as photoredox catalyst in oxidative and reductive quenching, in comparison with other photoca...
Scheme 11: C–O bond cleavage of 1-phenylethanol using a cobalt porphyrin (CoTMPP) under visible light.
Scheme 12: Hydration of terminal alkynes by RhIII(TSPP) under visible light irradiation.
Scheme 13: Regioselective photocatalytic hydro-defluorination of perfluoroarenes by RhIII(TSPP).
Scheme 14: Formation of 2-methyl-2,3-dihydrobenzofuran by intramolecular hydro-functionalization of allylpheno...
Scheme 15: Photocatalytic oxidative hydroxylation of arylboronic acids using UNLPF-12 as heterogeneous photoca...
Scheme 16: Photocatalytic oxidative hydroxylation of arylboronic acids using MOF-525 as heterogeneous photocat...
Scheme 17: Preparation of the heterogeneous photocatalyst CNH.
Scheme 18: Photoinduced sulfonation of alkenes with sulfinic acid using CNH as photocatalyst.
Scheme 19: Sulfonic acid scope of the sulfonation reactions.
Scheme 20: Regioselective sulfonation reaction of arimistane.
Scheme 21: Synthesis of quinazolin-4-(3H)-ones.
Scheme 22: Selective photooxidation of aromatic benzyl alcohols to benzaldehydes using Pt/PCN-224(Zn).
Scheme 23: Photooxidation of benzaldehydes to benzoic acids using Pt or Pd porphyrins.
Scheme 24: Photocatalytic reduction of various nitroaromatics using a Ni-MOF.
Scheme 25: Photoinduced cycloadditions of CO2 with epoxides by MOF1.
Figure 4: Electronic configurations of the species of oxygen. Adapted from [66].
Scheme 26: TPP-photocatalyzed generation of 1O2 and its application in organic synthesis. Adapted from [67-69].
Scheme 27: Pericyclic reactions involving singlet oxygen and their mechanisms. Adapted from [67].
Scheme 28: First scaled up ascaridole preparation from α-terpinene.
Scheme 29: Antimalarial drug synthesis using an endoperoxidation approach.
Scheme 30: Photooxygenation of colchicine.
Scheme 31: Synthesis of (−)-pinocarvone from abundant (+)-α-pinene.
Scheme 32: Seeberger’s semi-synthesis of artemisinin.
Scheme 33: Synthesis of artemisinin using TPP and supercritical CO2.
Scheme 34: Synthesis of artemisinin using chlorophyll a.
Scheme 35: Quercitol stereoisomer preparation.
Scheme 36: Photocatalyzed preparation of naphthoquinones.
Scheme 37: Continuous endoperoxidation of conjugated dienes and subsequent rearrangements leading to oxidized ...
Scheme 38: The Opatz group total synthesis of (–)-oxycodone.
Scheme 39: Biomimetic syntheses of rhodonoids A, B, E, and F.
Scheme 40: α-Photooxygenation of chiral aldehydes.
Scheme 41: Asymmetric photooxidation of indanone β-keto esters by singlet oxygen using PTC as a chiral inducer...
Scheme 42: Asymmetric photooxidation of both β-keto esters and β-keto amides by singlet oxygen using PTC-2 as ...
Scheme 43: Bifunctional photo-organocatalyst used for the asymmetric oxidation of β-keto esters and β-keto ami...
Scheme 44: Mechanism of singlet oxygen oxidation of sulfides to sulfoxides.
Scheme 45: Controlled oxidation of sulfides to sulfoxides using protonated porphyrins as photocatalysts. aIsol...
Scheme 46: Photochemical oxidation of sulfides to sulfoxides using PdTPFPP as photocatalyst.
Scheme 47: Controlled oxidation of sulfides to sulfoxides using SnPor@PAF as a photosensitizer.
Scheme 48: Syntheses of 2D-PdPor-COF and 3D-Pd-COF.
Scheme 49: Photocatalytic oxidation of A) thioanisole to methyl phenyl sulfoxide and B) various aryl sulfides,...
Scheme 50: General mechanism for oxidation of amines to imines.
Scheme 51: Oxidation of secondary amines to imines.
Scheme 52: Oxidation of secondary amines using Pd-TPFPP as photocatalyst.
Scheme 53: Oxidative amine coupling using UNLPF-12 as heterogeneous photocatalyst.
Scheme 54: Synthesis of Por-COF-1 and Por-COF-2.
Scheme 55: Photocatalytic oxidation of amines to imines by Por-COF-2.
Scheme 56: Photocyanation of primary amines.
Scheme 57: Synthesis of ᴅ,ʟ-tert-leucine hydrochloride.
Scheme 58: Photocyanation of catharanthine and 16-O-acetylvindoline using TPP.
Scheme 59: Photochemical α-functionalization of N-aryltetrahydroisoquinolines using Pd-TPFPP as photocatalyst.
Scheme 60: Ugi-type reaction with 1,2,3,4-tetrahydroisoquinoline using molecular oxygen and TPP.
Scheme 61: Ugi-type reaction with dibenzylamines using molecular oxygen and TPP.
Scheme 62: Mannich-type reaction of tertiary amines using PdTPFPP as photocatalyst.
Scheme 63: Oxidative Mannich reaction using UNLPF-12 as heterogeneous photocatalyst.
Scheme 64: Transformation of amines to α-cyanoepoxides and the proposed mechanism.
Beilstein J. Org. Chem. 2020, 16, 409–414, doi:10.3762/bjoc.16.39
Graphical Abstract
Scheme 1: Synthetic methods of six-membered silacyclic compounds.
Scheme 2: Scope of dihydrosilanes. Conditions: a: conditions B (Table 1, entry 5); b: conditions A (Table 1, entry 3).
Scheme 3: Scope of diaryl ether and diaryl thioether derivatives. Conditions: a: conditions B (Table 1, entry 5); b:...
Scheme 4: Gram-scale Synthesis of 3a.
Scheme 5: Transformation of the amino groups in 3a.
Beilstein J. Org. Chem. 2020, 16, 200–211, doi:10.3762/bjoc.16.23
Graphical Abstract
Figure 1: Chemical structure of representative approved drugs containing a spirocyclic moiety.
Scheme 1: Synthetic strategies for accessing pyrrolocyclopentenone derivatives, including the novel couple/pa...
Scheme 2: Couple/pair approach using combined KA2 and Pauson–Khand multicomponent reactions.
Scheme 3: Follow-up chemistry on compound 5 taking advantage of the enone chemistry. Reaction conditions. (i)...
Figure 2: Top: Selected NOE contacts from NOESY 1D spectra of compound 36; bottom: low energy conformer of 36...
Figure 3: PCA plot resulting from the correlation between PC1 vs PC2, showing the positioning in the chemical...
Figure 4: PMI plot showing the skeletal diversity of compounds 3–39 (blue diamonds) with respect to the refer...
Beilstein J. Org. Chem. 2020, 16, 60–70, doi:10.3762/bjoc.16.8
Graphical Abstract
Scheme 1: Pyrrole–imidazole–azobenzene polyamides and the dsDNA target sequences employed in this study.
Scheme 2: Building blocks required for the synthesis of the photoswitchable Im/Py polyamides. A) Fmoc–Azo–OH 1...
Figure 1: Section of the 1H NMR (600 MHz) spectrum of polyamide P1. A) Initial thermal equilibrium. B) After ...
Figure 2: E/Z isomer ratio of the polyamides P1–P3. Values were obtained from the respective 1H NMR experimen...
Figure 3: Titration experiments of target DNA sequences with P1–P3 in the photostationary Z-state and the the...
Figure 4: Titration of DNA containing single mutations (in bold) with P1–P3 in the photostationary Z-state an...
Beilstein J. Org. Chem. 2019, 15, 2864–2871, doi:10.3762/bjoc.15.280
Graphical Abstract
Figure 1: Hydantoin-based commercially available drugs.
Scheme 1: Pseudothiohydantoin–thiohydantoin rearrangement.
Scheme 2: Syntheses of regioisomeric 5-spiro-substituted thiohydantoins and pseudothiohydantoins: previous [10] a...
Figure 2: Electrophilic centers of FPDs 1, starting materials of this study.
Scheme 3: Cyclocondensation of FPDs 1 with 1,3-binucleophilic reagents, resulting in pyrrole-2-one-bearing sp...
Scheme 4: Reaction of FPD 1a with thiourea.
Scheme 5: PTR of 3a to 2a.
Scheme 6: Pathways for the formation of compound 2a.
Scheme 7: Reaction of FPD 1a with monosubstituted thioureas.
Scheme 8: Reaction of FPDs 1 with 1,3-dibutylthiourea at room temperature.
Scheme 9: Plausible PTR pathways.
Beilstein J. Org. Chem. 2019, 15, 2822–2829, doi:10.3762/bjoc.15.275
Graphical Abstract
Scheme 1: Synthesis of hemi-indigo derivatives Z-1a–c.
Scheme 2: Synthetic routes to alkylamino-substituted dimethoxy hemi-indigo Z-1c.
Figure 1: Photoswitching of hemi-indigo derivatives: (A) Z-1a, c = 20 μM in H2O with 10% (v/v) DMSO, λex = 42...
Scheme 3: Photoswitching of hemi-indigo derivatives.
Figure 2: Absorption spectra of the Z-isomer (black), two photostationary states obtained upon irradiation wi...
Beilstein J. Org. Chem. 2019, 15, 2678–2683, doi:10.3762/bjoc.15.261
Graphical Abstract
Figure 1: An example of an earlier developed S,N-heterohexacene [13] and general structure of compounds synthesiz...
Scheme 1: Synthesis of aryl-substituted TT derivatives 3a–k, product scope, and yields.
Scheme 2: Synthesis of thieno[3,2-b]thiophen-3(2H)-one 4a–k, product scope, and yields.
Scheme 3: Synthesis of TTI derivatives 6a–o, substrate and product scopes, and yields.
Scheme 4: Alkylation of TTI 6d.
Figure 2: ORTEP diagram for the X-ray structure of compound 7d. Thermal ellipsoids of 50% probability are sho...
Beilstein J. Org. Chem. 2019, 15, 2664–2670, doi:10.3762/bjoc.15.259
Graphical Abstract
Scheme 1: Synthesis of compound 1.
Figure 1: X-ray structure of compound 1 (one of the two enantiomers present in the crystal).
Scheme 2: Possible mechanism for the formation of 1.
Figure 2: A possible mechanism for the trans-position of the methyne hydrogens in the azepine ring: the elect...
Figure 3: Selective formation of a single diastereomer in the 1,3-dipolar cycloaddition reaction.
Scheme 3: Synthesis of nitroxide 6.
Figure 4: X-ray structure of compound 6 (one of the two enantiomers present in the crystal).
Scheme 4: A proposed mechanism for nitroxide 6 synthesis.
Figure 5: A, B) Temperature dependence of the electron spin relaxation times in water/glycerol at X-band freq...
Beilstein J. Org. Chem. 2019, 15, 2623–2630, doi:10.3762/bjoc.15.255
Graphical Abstract
Scheme 1: Two modes of reactions of alkynes by silver catalysis.
Scheme 2: Reactions of ynamides or ynol ethers with isoxazoles by transition metal catalysis.
Figure 1: Selected bioactive molecules containing the 5-amino-1H-pyrrole-3-carboxamide motif.
Scheme 3: Reactions of ynamide 4a with different isoxazoles 5, 7 and 8a.
Figure 2: Scope with regard to ynamide 4. All reactions were carried out with ynamide 4 (0.2 mmol), isoxazole ...
Figure 3: Scope with regard to the 5-aminoisoxazole 8 (see Figure 2). aReaction conditions: 2.0 equiv of 8e, 100 °C.
Figure 4: Molecular structure in the solid state of compound 10ad.
Scheme 4: A gram-scale experiment.
Scheme 5: Mechanistic hypotheses for Ag-catalyzed reaction of ynamide 4a with aminoisoxazole 8a.
Scheme 6: Possible reaction routes of intermediate C.
Beilstein J. Org. Chem. 2019, 15, 2419–2427, doi:10.3762/bjoc.15.234
Graphical Abstract
Figure 1: Oxazolone pseudodipeptide 1 and tetrapeptide 2a.
Scheme 1: Synthesis of linear azido ester dipeptide 5 and tetrapeptide 7.
Scheme 2: Synthesis of oxazolone pseudopeptides 1, 2a and 2b.
Figure 2: Characteristic NOEs of 2a.
Figure 3: DMSO titration study of 2a.
Figure 4: 1H NMR temperature study of 2a.
Figure 5: Optimized helical conformations of (A) 2a, (B) 2b and (C) 9.
Figure 6: Ion transport activity (A) for 1, (B) for 2a, across EYPC-LUVs HPTS.
Figure 7: Cation (A) and anion (B) transport activity of 2a.
Figure 8:
Comparison of the ion transport activity of 2a and 2b at 20 µM across EYPC-LUVslucigenin (A). Conce...
Beilstein J. Org. Chem. 2019, 15, 2170–2183, doi:10.3762/bjoc.15.214
Graphical Abstract
Figure 1: Selisistat (1) and hit compound GW435821X (2a).
Scheme 1: Reagents and conditions: a) appropriate boronic acid, Pd(PPh3)4, Na2CO3, DMF, H2O, microwave, 15 mi...
Scheme 2: Reagents and conditions: a) Pd2(dba)3 or Pd(OAc)2, P(o-tol)3, TEA, DMF, 120–140 °C, 0.7–24 h, 11–75...
Figure 2: (Left) UV–vis spectrum of 2b 50 µM in 5% DMSO (v/v) in assay buffer after varying durations of irra...
Figure 3: (Left) LC chromatogram of the LC–HRMS analysis of 2b after varying durations of irradiation with 25...
Scheme 3: Photocyclization and oxidation reaction of 2b upon UV irradiation.
Figure 4: Calculated and experimental absorption spectra of compounds (E)-2b-B (A), (Z)-2b-A (B), and product...
Scheme 4: Reagents and conditions: a) 4-fluoroaniline, oxone, HAc, 60 °C, 14 d, 42%; b) NH3, MeOH, rt, 3 d, 9...
Figure 5: (Left) UV–vis spectrum of 11, 50 µM in 5% DMSO (v/v), in assay buffer at the thermal equilibrium an...
Beilstein J. Org. Chem. 2019, 15, 2036–2042, doi:10.3762/bjoc.15.200
Graphical Abstract
Figure 1: Structure of nitroxide 1.
Scheme 1: The synthesis of aldonitrones 5a–c.
Scheme 2: The principal synthetic scheme for nitroxides 12a–c.
Scheme 3: A possible pathway of ketonitrone 7c self-transformations.
Scheme 4: Oxidation of aminoalcohol 9a.
Scheme 5: The synthesis of alkoxyamines 16a–c.
Scheme 6: The alkoxyamine 18 synthesis.
Scheme 7: A possible mechanism of nitroxide 17 formation.
Scheme 8: Optimisation of the synthesis of nitroxide 1.
Figure 2: Kinetics of the reduction of nitroxides 1 and 12a–c (0.3 mM) with ascorbate (50 mM) in 50 mM phosph...
Beilstein J. Org. Chem. 2019, 15, 1933–1944, doi:10.3762/bjoc.15.189
Graphical Abstract
Figure 1: The structure of the sesquiterpene lactones archangelolide (1) and trilobolide (2).
Scheme 1: Reagents and conditions: a) MeOH, TEA, 48 h, yield 32%; b) (i) 5-azidopentanoic acid, DCC, DCM, 90 ...
Figure 2: Intracellular localization of archangelolide-dansyl (5) in human cells from osteosarcoma (U-2 OS). ...
Figure 3: Co-localization of dansylarchangelolide 5 with a marker of endoplasmic reticulum (top row) and with...
Figure 4: Cartoon representation of sarco/endoplasmic reticulum Ca2+ ATPase binding pocket with A, C) archang...
Figure 5: Molecular surface representation of sarco/endoplasmic reticulum Ca2+ ATPase binding pocket with A) ...
Figure 6: Structural formulae of (i) thapsigargin, (ii) trilobolide (2), and (iii) archangelolide (1). Red pa...
Figure 7: Viability of rat peritoneal cells treated with archangelolide (1), dansylarchangelolide 5 and dansy...
Figure 8: NO production in primary rat macrophages. The cells were treated with archangelolide (1) and dansyl...
Figure 9: Evaluation of cytokine TNF-α secretion in rat peritoneal cells. Stimulation of primary cells was in...
Figure 10: Structure of laserolide.
Beilstein J. Org. Chem. 2019, 15, 1907–1912, doi:10.3762/bjoc.15.186
Graphical Abstract
Figure 1: Representative sulfonyl fluoride compounds applied in medicinal chemistry and chemical biology.
Scheme 1: Synthesis background of N-fluorosulfonyl amides and fluorosulfates.
Scheme 2: Screening of the substrate scope of amides. Reaction conditions: a mixture of amides 1 (1.0 mmol), ...
Scheme 3: Amide resonance model and X-ray single crystal structure of 4e (CCDC 1906002).
Scheme 4: The proposed reaction mechanism.
Beilstein J. Org. Chem. 2019, 15, 1722–1757, doi:10.3762/bjoc.15.168
Graphical Abstract
Figure 1: Examples of three-carbon chirons.
Figure 2: Structures of derivatives of N-(1-phenylethyl)aziridine-2-carboxylic acid 5–8.
Figure 3: Synthetic equivalency of aziridine aldehydes 6.
Scheme 1: Synthesis of N-(1-phenylethyl)aziridine-2-carboxylates 5. Reagents and conditions: a) TEA, toluene,...
Scheme 2: Absolute configuration at C2 in (2S,1'S)-5a. Reagents and conditions: a) 20% HClO4, 80 °C, 30 h the...
Scheme 3: Major synthetic strategies for a 2-ketoaziridine scaffold [R* = (R)- or (S)-1-phenylethyl; R′ = Alk...
Scheme 4: Synthesis of cyanide (2S,1'S)-13. Reagents and conditions: a) NH3, EtOH/H2O, rt, 72 h; b) Ph3P, CCl4...
Scheme 5: Synthesis of key intermediates (R)-16 and (R)-17 for (R,R)-formoterol (14) and (R)-tamsulosin (15)....
Scheme 6: Synthesis of mitotic kinesin inhibitors (2R/S,1'R)-23. Reagents and conditions: a) H2, Pd(OH)2, EtO...
Scheme 7: Synthesis of (R)-mexiletine ((R)-24). Reagents and conditions: a) TsCl, TEA, DMAP, CH2Cl2, rt, 1 h;...
Scheme 8: Synthesis of (−)-cathinone ((S)-27). Reagents and conditions: a) PhMgBr, ether, 0 °C; b) H2, 10% Pd...
Scheme 9: Synthesis of N-Boc-norpseudoephedrine ((1S,2S)-(+)-29) and N-Boc-norephedrine ((1R,2S)-29). Reagent...
Scheme 10: Synthesis of (−)-ephedrine ((1R,2S)-31). Reagents and conditions: a) TfOMe, MeCN then NaBH3CN, rt; ...
Scheme 11: Synthesis of xestoaminol C ((2S,3R)-35), 3-epi-xestoaminol C ((2S,3S)-35) and N-Boc-spisulosine ((2S...
Scheme 12: Synthesis of ʟ-tryptophanol ((S)-41). Reagents and conditions: a) CDI, MeCN, rt, 1 h then TMSI, MeC...
Scheme 13: Synthesis of ʟ-homophenylalaninol ((S)-42). Reagents and conditions: a) NaH, THF, 0 °C to −78 °C, 1...
Scheme 14: Synthesis of ᴅ-homo(4-octylphenyl)alaninol ((R)-47) and a sphingolipid analogue (R)-48. Reagents an...
Scheme 15: Synthesis of florfenicol ((1R,2S)-49). Reagents and conditions: a) (S)-1-phenylethylamine, TEA, MeO...
Scheme 16: Synthesis of natural tyroscherin ((2S,3R,6E,8R,10R)-55). Reagents and conditions: a) I(CH2)3OTIPS, t...
Scheme 17: Syntheses of (−)-hygrine (S)-61, (−)-hygroline (2S,2'S)-62 and (−)-pseudohygroline (2S,2'R)-62. Rea...
Scheme 18: Synthesis of pyrrolidine (3S,3'R)-68, a fragment of the fluoroquinolone antibiotic PF-00951966. Rea...
Scheme 19: Synthesis of sphingolipid analogues (R)-76. Reagents and conditions: a) BnBr, Mg, THF, reflux, 6 h;...
Scheme 20: Synthesis of ᴅ-threo-PDMP (1R,2R)-81. Reagents and conditions: a) TMSCl, NaI, MeCN, rt, 1 h 50 min,...
Scheme 21: Synthesis of the sphingolipid analogue SG-14 (2S,3S)-84. Reagents and conditions: a) LiAlH4, THF, 0...
Scheme 22: Synthesis of the sphingolipid analogue SG-12 (2S,3R)-88. Reagents and conditions: a) 1-(bromomethyl...
Scheme 23: Synthesis of sphingosine-1-phosphate analogues DS-SG-44 and DS-SG-45 (2S,3R)-89a and (2S,3R)-89a. R...
Scheme 24: Synthesis of N-Boc-safingol ((2S,3S)-95) and N-Boc-ᴅ-erythro-sphinganine ((2S,3R)-95). Reagents and...
Scheme 25: Synthesis of ceramide analogues (2S,3R)-96. Reagents and conditions: a) NaBH4, ZnCl2, MeOH, −78 °C,...
Scheme 26: Synthesis of orthogonally protected serinols, (S)-101 and (R)-102. Reagents and conditions: a) BnBr...
Scheme 27: Synthesis of N-acetyl-3-phenylserinol ((1R,2R)-105). Reagents and conditions: a) AcOH, CH2Cl2, refl...
Scheme 28: Synthesis of (S)-linezolid (S)-107. Reagents and conditions: a) LiAlH4, THF, 0 °C to reflux; b) Boc2...
Scheme 29: Synthesis of (2S,3S,4R)-2-aminooctadecane-1,3,4-triol (ᴅ-ribo-phytosphingosine) (2S,3S,4R)-110. Rea...
Scheme 30: Syntheses of ᴅ-phenylalanine (R)-116. Reagents and conditions: a) AcOH, CH2Cl2, reflux, 4 h; b) MsC...
Scheme 31: Synthesis of N-Boc-ᴅ-3,3-diphenylalanine ((R)-122). Reagents and conditions: a) PhMgBr, THF, −78 °C...
Scheme 32: Synthesis of ethyl N,N’-di-Boc-ʟ-2,3-diaminopropanoate ((S)-125). Reagents and conditions: a) NaN3,...
Scheme 33: Synthesis of the bicyclic amino acid (S)-(+)-127. Reagents and conditions: a) BF3·OEt2, THF, 60 °C,...
Scheme 34: Synthesis of lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-130. Reagents and condit...
Scheme 35: Synthesis of N-Boc-norfuranomycin ((2S,2'R)-133). Reagents and conditions: a) H2C=CHCH2I, NaH, THF,...
Scheme 36: Synthesis of MeBmt (2S,3R,4R,6E)-139. Reagents and conditions: a) diisopropyl (S,S)-tartrate (E)-cr...
Scheme 37: Synthesis of (+)-polyoxamic acid (2S,3S,4S)-144. Reagents and conditions: a) AD-mix-α, MeSO2NH2, t-...
Scheme 38: Synthesis of the protected 3-hydroxy-ʟ-glutamic acid (2S,3R)-148. Reagents and conditions: a) LiHMD...
Scheme 39: Synthesis of (+)-isoserine (R)-152. Reagents and conditions: a) AcCl, MeCN, rt, 0.5 h then Na2CO3, ...
Scheme 40: Synthesis of (3R,4S)-N3-Boc-3,4-diaminopentanoic acid (3R,4S)-155. Reagents and conditions: a) Ph3P...
Scheme 41: Synthesis of methyl (2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoate (2S,3S,4S)-159. ...
Scheme 42: Syntheses of methyl (3S,4S) 4,5-di-N-Boc-amino-3-hydroxypentanoate ((3S,4S)-164), methyl (3S,4S)-4-N...
Scheme 43: Syntheses of (3R,5S)-5-(aminomethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one ((3R,5S)-168). Reage...
Scheme 44: Syntheses of a series of imidazolin-2-one dipeptides 175–177 (for R' and R'' see text). Reagents an...
Scheme 45: Syntheses of (2S,3S)-N-Boc-3-hydroxy-2-hydroxymethylpyrrolidine ((2S,3S)-179). Reagents and conditi...
Scheme 46: Syntheses of enantiomers of 1,4-dideoxy-1,4-imino-ʟ- and -ᴅ-lyxitols (2S,3R,4S)-182 and (2R,3S,4R)-...
Scheme 47: Synthesis of 1,4-dideoxy-1,4-imino-ʟ-ribitol (2S,3S,4R)-182. Reagents and conditions: a) AcOH, CH2Cl...
Scheme 48: Syntheses of 1,4-dideoxy-1,4-imino-ᴅ-arabinitol (2R,3R,4R)-182 and 1,4-dideoxy-1,4-imino-ᴅ-xylitol ...
Scheme 49: Syntheses of natural 2,5-imino-2,5,6-trideoxy-ʟ-gulo-heptitol ((2S,3R,4R,5R)-184) and its C4 epimer...
Scheme 50: Syntheses of (−)-dihydropinidine ((2S,6R)-187a) (R = C3H7) and (2S,6R)-isosolenopsins (2S,6R)-187b ...
Scheme 51: Syntheses of (+)-deoxocassine ((2S,3S,6R)-190a, R = C12H25) and (+)-spectaline ((2S,3S,6R)-190b, R ...
Scheme 52: Synthesis of (−)-microgrewiapine A ((2S,3R,6S)-194a) and (+)-microcosamine A ((2S,3R,6S)-194b). Rea...
Scheme 53: Syntheses of ʟ-1-deoxynojirimycin ((2S,3S,4S,5R)-200), ʟ-1-deoxymannojirimycin ((2S,3S,4S,5S)-200) ...
Scheme 54: Syntheses of 1-deoxy-ᴅ-galacto-homonojirimycin (2R,3S,4R,5S)-211. Reagents and conditions: a) MeONH...
Scheme 55: Syntheses of 7a-epi-hyacinthacine A1 (1S,2R,3R,7aS)-220. Reagents and conditions: a) TfOTBDMS, 2,6-...
Scheme 56: Syntheses of 8-deoxyhyacinthacine A1 ((1S,2R,3R,7aR)-221). Reagents and conditions: a) H2, Pd/C, PT...
Scheme 57: Syntheses of (+)-lentiginosine ((1S,2S,8aS)-227). Reagents and conditions: a) (EtO)2P(O)CH2COOEt, L...
Scheme 58: Syntheses of 8-epi-swainsonine (1S,2R,8S,8aR)-231. Reagents and conditions: a) Ph3P=CHCOOMe, MeOH, ...
Scheme 59: Synthesis of a protected vinylpiperidine (2S,3R)-237, a key intermediate in the synthesis of (−)-sw...
Scheme 60: Synthesis of a modified carbapenem 245. Reagents and conditions: a) AcOEt, LiHMDS, THF, −78 °C, 1.5...
Beilstein J. Org. Chem. 2019, 15, 1612–1704, doi:10.3762/bjoc.15.165
Graphical Abstract
Figure 1: Various drugs having IP nucleus.
Figure 2: Participation percentage of various TMs for the syntheses of IPs.
Scheme 1: CuI–NaHSO4·SiO2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 2: Experimental examination of reaction conditions.
Scheme 3: One-pot tandem reaction for the synthesis of 2-haloimidazopyridines.
Scheme 4: Mechanistic scheme for the synthesis of 2-haloimidazopyridine.
Scheme 5: Copper-MOF-catalyzed three-component reaction (3-CR) for imidazo[1,2-a]pyridines.
Scheme 6: Mechanism for copper-MOF-driven synthesis.
Scheme 7: Heterogeneous synthesis via titania-supported CuCl2.
Scheme 8: Mechanism involving oxidative C–H functionalization.
Scheme 9: Heterogeneous synthesis of IPs.
Scheme 10: One-pot regiospecific synthesis of imidazo[1,2-a]pyridines.
Scheme 11: Vinyl azide as an unprecedented substrate for imidazo[1,2-a]pyridines.
Scheme 12: Radical pathway.
Scheme 13: Cu(I)-catalyzed transannulation approach for imidazo[1,5-a]pyridines.
Scheme 14: Plausible radical pathway for the synthesis of imidazo[1,5-a]pyridines.
Scheme 15: A solvent-free domino reaction for imidazo[1,2-a]pyridines.
Scheme 16: Cu-NPs-mediated synthesis of imidazo[1,2-a]pyridines.
Scheme 17: CuI-catalyzed synthesis of isoxazolylimidazo[1,2-a]pyridines.
Scheme 18: Functionalization of 4-bromo derivative via Sonogashira coupling reaction.
Scheme 19: A plausible reaction pathway.
Scheme 20: Cu(I)-catalyzed intramolecular oxidative C–H amidation reaction.
Scheme 21: One-pot synthetic reaction for imidazo[1,2-a]pyridine.
Scheme 22: Plausible reaction mechanism.
Scheme 23: Cu(OAc)2-promoted synthesis of imidazo[1,2-a]pyridines.
Scheme 24: Mechanism for aminomethylation/cycloisomerization of propiolates with imines.
Scheme 25: Three-component synthesis of imidazo[1,2-a]pyridines.
Figure 3: Scope of pyridin-2(1H)-ones and acetophenones.
Scheme 26: CuO NPS-promoted A3 coupling reaction.
Scheme 27: Cu(II)-catalyzed C–N bond formation reaction.
Scheme 28: Mechanism involving Chan–Lam/Ullmann coupling.
Scheme 29: Synthesis of formyl-substituted imidazo[1,2-a]pyridines.
Scheme 30: A tandem sp3 C–H amination reaction.
Scheme 31: Probable mechanistic approach.
Scheme 32: Dual catalytic system for imidazo[1,2-a]pyridines.
Scheme 33: Tentative mechanism.
Scheme 34: CuO/CuAl2O4/ᴅ-glucose-promoted 3-CCR.
Scheme 35: A tandem CuOx/OMS-2-based synthetic strategy.
Figure 4: Biomimetic catalytic oxidation in the presence of electron-transfer mediators (ETMs).
Scheme 36: Control experiment.
Scheme 37: Copper-catalyzed C(sp3)–H aminatin reaction.
Scheme 38: Reaction of secondary amines.
Scheme 39: Probable mechanistic pathway.
Scheme 40: Coupling reaction of α-azidoketones.
Scheme 41: Probable pathway.
Scheme 42: Probable mechanism with free energy calculations.
Scheme 43: MCR for cyanated IP synthesis.
Scheme 44: Substrate scope for the reaction.
Scheme 45: Reaction mechanism.
Scheme 46: Probable mechanistic pathway for Cu/ZnAl2O4-catalyzed reaction.
Scheme 47: Copper-catalyzed double oxidative C–H amination reaction.
Scheme 48: Application towards different coupling reactions.
Scheme 49: Reaction mechanism.
Scheme 50: Condensation–cyclization approach for the synthesis of 1,3-diarylated imidazo[1,5-a]pyridines.
Scheme 51: Optimized reaction conditions.
Scheme 52: One-pot 2-CR.
Scheme 53: One-pot 3-CR without the isolation of chalcone.
Scheme 54: Copper–Pybox-catalyzed cyclization reaction.
Scheme 55: Mechanistic pathway catalyzed by Cu–Pybox complex.
Scheme 56: Cu(II)-promoted C(sp3)-H amination reaction.
Scheme 57: Wider substrate applicability for the reaction.
Scheme 58: Plausible reaction mechanism.
Scheme 59: CuI assisted C–N cross-coupling reaction.
Scheme 60: Probable reaction mechanism involving sp3 C–H amination.
Scheme 61: One-pot MCR-catalyzed by CoFe2O4/CNT-Cu.
Scheme 62: Mechanistic pathway.
Scheme 63: Synthetic scheme for 3-nitroimidazo[1,2-a]pyridines.
Scheme 64: Plausible mechanism for CuBr-catalyzed reaction.
Scheme 65: Regioselective synthesis of halo-substituted imidazo[1,2-a]pyridines.
Scheme 66: Synthesis of 2-phenylimidazo[1,2-a]pyridines.
Scheme 67: Synthesis of diarylated compounds.
Scheme 68: CuBr2-mediated one-pot two-component oxidative coupling reaction.
Scheme 69: Decarboxylative cyclization route to synthesize 1,3-diarylimidazo[1,5-a]pyridines.
Scheme 70: Mechanistic pathway.
Scheme 71: C–H functionalization reaction of enamines to produce diversified heterocycles.
Scheme 72: A plausible mechanism.
Scheme 73: CuI-promoted aerobic oxidative cyclization reaction of ketoxime acetates and pyridines.
Scheme 74: CuI-catalyzed pathway for the formation of imidazo[1,2-a]pyridine.
Scheme 75: Mechanistic pathway.
Scheme 76: Mechanistic rationale for the synthesis of products.
Scheme 77: Copper-catalyzed synthesis of vinyloxy-IP.
Scheme 78: Regioselective product formation with propiolates.
Scheme 79: Proposed mechanism for vinyloxy-IP formation.
Scheme 80: Regioselective synthesis of 3-hetero-substituted imidazo[1,2-a]pyridines with different reaction su...
Scheme 81: Mechanistic pathway.
Scheme 82: CuI-mediated synthesis of 3-formylimidazo[1,2-a]pyridines.
Scheme 83: Radical pathway for 3-formylated IP synthesis.
Scheme 84: Pd-catalyzed urea-cyclization reaction for IPs.
Scheme 85: Pd-catalyzed one-pot-tandem amination and intramolecular amidation reaction.
Figure 5: Scope of aniline nucleophiles.
Scheme 86: Pd–Cu-catalyzed Sonogashira coupling reaction.
Scheme 87: One-pot amide coupling reaction for the synthesis of imidazo[4,5-b]pyridines.
Scheme 88: Urea cyclization reaction for the synthesis of two series of pyridines.
Scheme 89: Amidation reaction for the synthesis of imidazo[4,5-b]pyridines.
Figure 6: Amide scope.
Scheme 90: Pd NPs-catalyzed 3-component reaction for the synthesis of 2,3-diarylated IPs.
Scheme 91: Plausible mechanistic pathway for Pd NPs-catalyzed MCR.
Scheme 92: Synthesis of chromenoannulated imidazo[1,2-a]pyridines.
Scheme 93: Mechanism for the synthesis of chromeno-annulated IPs.
Scheme 94: Zinc oxide NRs-catalyzed synthesis of imidazo[1,2-a]azines/diazines.
Scheme 95: Zinc oxide-catalyzed isocyanide based GBB reaction.
Scheme 96: Reaction pathway for ZnO-catalyzed GBB reaction.
Scheme 97: Mechanistic pathway.
Scheme 98: ZnO NRs-catalyzed MCR for the synthesis of imidazo[1,2-a]azines.
Scheme 99: Ugi type GBB three-component reaction.
Scheme 100: Magnetic NPs-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 101: Regioselective synthesis of 2-alkoxyimidazo[1,2-a]pyridines catalyzed by Fe-SBA-15.
Scheme 102: Plausible mechanistic pathway for the synthesis of 2-alkoxyimidazopyridine.
Scheme 103: Iron-catalyzed synthetic approach.
Scheme 104: Iron-catalyzed aminooxygenation reaction.
Scheme 105: Mechanistic pathway.
Scheme 106: Rh(III)-catalyzed double C–H activation of 2-substituted imidazoles and alkynes.
Scheme 107: Plausible reaction mechanism.
Scheme 108: Rh(III)-catalyzed non-aromatic C(sp2)–H bond activation–functionalization for the synthesis of imid...
Scheme 109: Reactivity and selectivity of different substrates.
Scheme 110: Rh-catalyzed direct C–H alkynylation by Li et al.
Scheme 111: Suggested radical mechanism.
Scheme 112: Scandium(III)triflate-catalyzed one-pot reaction and its mechanism for the synthesis of benzimidazo...
Scheme 113: RuCl3-assisted Ugi-type Groebke–Blackburn condensation reaction.
Scheme 114: C-3 aroylation via Ru-catalyzed two-component reaction.
Scheme 115: Regioselective synthetic mechanism.
Scheme 116: La(III)-catalyzed one-pot GBB reaction.
Scheme 117: Mechanistic approach for the synthesis of imidazo[1,2-a]pyridines.
Scheme 118: Synthesis of imidazo[1,2-a]pyridine using LaMnO3 NPs under neat conditions.
Scheme 119: Mechanistic approach.
Scheme 120: One-pot 3-CR for regioselective synthesis of 2-alkoxy-3-arylimidazo[1,2-a]pyridines.
Scheme 121: Formation of two possible products under optimization of the catalysts.
Scheme 122: Mechanistic strategy for NiFe2O4-catalyzed reaction.
Scheme 123: Two-component reaction for synthesizing imidazodipyridiniums.
Scheme 124: Mechanistic scheme for the synthesis of imidazodipyridiniums.
Scheme 125: CuI-catalyzed arylation of imidazo[1,2-a]pyridines.
Scheme 126: Mechanism for arylation reaction.
Scheme 127: Cupric acetate-catalyzed double carbonylation approach.
Scheme 128: Radical mechanism for double carbonylation of IP.
Scheme 129: C–S bond formation reaction catalyzed by cupric acetate.
Scheme 130: Cupric acetate-catalyzed C-3 formylation approach.
Scheme 131: Control experiments for signifying the role of DMSO and oxygen.
Scheme 132: Mechanism pathway.
Scheme 133: Copper bromide-catalyzed CDC reaction.
Scheme 134: Extension of the substrate scope.
Scheme 135: Plausible radical pathway.
Scheme 136: Transannulation reaction for the synthesis of imidazo[1,5-a]pyridines.
Scheme 137: Plausible reaction pathway for denitrogenative transannulation.
Scheme 138: Cupric acetate-catalyzed C-3 carbonylation reaction.
Scheme 139: Plausible mechanism for regioselective C-3 carbonylation.
Scheme 140: Alkynylation reaction at C-2 of 3H-imidazo[4,5-b]pyridines.
Scheme 141: Two-way mechanism for C-2 alkynylation of 3H-imidazo[4,5-b]pyridines.
Scheme 142: Palladium-catalyzed SCCR approach.
Scheme 143: Palladium-catalyzed Suzuki coupling reaction.
Scheme 144: Reaction mechanism.
Scheme 145: A phosphine free palladium-catalyzed synthesis of C-3 arylated imidazopyridines.
Scheme 146: Palladium-mediated Buchwald–Hartwig cross-coupling reaction.
Figure 7: Structure of the ligands optimized.
Scheme 147: Palladium acetate-catalyzed direct arylation of imidazo[1,2-a]pyridines.
Scheme 148: Palladium acetate-catalyzed mechanistic pathway.
Scheme 149: Palladium acetate-catalyzed regioselective arylation reported by Liu and Zhan.
Scheme 150: Mechanism for selective C-3 arylation of IP.
Scheme 151: Pd(II)-catalyzed alkenylation reaction with styrenes.
Scheme 152: Pd(II)-catalyzed alkenylation reaction with acrylates.
Scheme 153: A two way mechanism.
Scheme 154: Double C–H activation reaction catalyzed by Pd(OAc)2.
Scheme 155: Probable mechanism.
Scheme 156: Palladium-catalyzed decarboxylative coupling.
Scheme 157: Mechanistic cycle for decarboxylative arylation reaction.
Scheme 158: Ligand-free approach for arylation of imidazo[1,2-a]pyridine-3-carboxylic acids.
Scheme 159: Mechanism for ligandless arylation reaction.
Scheme 160: NHC-Pd(II) complex assisted arylation reaction.
Scheme 161: C-3 arylation of imidazo[1,2-a]pyridines with aryl bromides catalyzed by Pd(OAc)2.
Scheme 162: Pd(II)-catalyzed C-3 arylations with aryl tosylates and mesylates.
Scheme 163: CDC reaction for the synthesis of imidazo[1,2-a]pyridines.
Scheme 164: Plausible reaction mechanism for Pd(OAc)2-catalyzed synthesis of imidazo[1,2-a]pyridines.
Scheme 165: Pd-catalyzed C–H amination reaction.
Scheme 166: Mechanism for C–H amination reaction.
Scheme 167: One-pot synthesis for 3,6-di- or 2,3,6-tri(hetero)arylimidazo[1,2-a]pyridines.
Scheme 168: C–H/C–H cross-coupling reaction of IPs and azoles catalyzed by Pd(II).
Scheme 169: Mechanistic cycle.
Scheme 170: Rh-catalyzed C–H arylation reaction.
Scheme 171: Mechanistic pathway for C–H arylation of imidazo[1,2-a]pyridine.
Scheme 172: Rh(III)-catalyzed double C–H activation of 2-phenylimidazo[1,2-a]pyridines and alkynes.
Scheme 173: Rh(III)-catalyzed mechanistic pathway.
Scheme 174: Rh(III)-mediated oxidative coupling reaction.
Scheme 175: Reactions showing functionalization of the product obtained by the group of Kotla.
Scheme 176: Mechanism for Rh(III)-catalyzed oxidative coupling reaction.
Scheme 177: Rh(III)-catalyzed C–H activation reaction.
Scheme 178: Mechanistic cycle.
Scheme 179: Annulation reactions of 2-arylimidazo[1,2-a]pyridines and alkynes.
Scheme 180: Two-way reaction mechanism for annulations reaction.
Scheme 181: [RuCl2(p-cymene)]2-catalyzed C–C bond formation reaction.
Scheme 182: Reported reaction mechanism.
Scheme 183: Fe(III) catalyzed C-3 formylation approach.
Scheme 184: SET mechanism-catalyzed by Fe(III).
Scheme 185: Ni(dpp)Cl2-catalyzed KTC coupling.
Scheme 186: Pd-catalyzed SM coupling.
Scheme 187: Vanadium-catalyzed coupling of IP and NMO.
Scheme 188: Mechanistic cycle.
Scheme 189: Selective C3/C5–H bond functionalizations by mono and bimetallic systems.
Scheme 190: rGO-Ni@Pd-catalyzed C–H bond arylation of imidazo[1,2-a]pyridine.
Scheme 191: Mechanistic pathway for heterogeneously catalyzed arylation reaction.
Scheme 192: Zinc triflate-catalyzed coupling reaction of substituted propargyl alcohols.
Beilstein J. Org. Chem. 2019, 15, 1491–1504, doi:10.3762/bjoc.15.151
Graphical Abstract
Figure 1: Allenes 1a–j used in this study.
Scheme 1: Transformations of allene 1g in TfOH leading to the formation of cations E1, E2 and E4 including se...
Figure 2: 31P NMR monitoring of the progress of transformation of E1 into E2 and E4 in TfOH at room temperatu...
Scheme 2: Results of the hydrolysis of cations A–H.
Scheme 3: Preparation of amides 6a,b from cations A, B, and F–H.
Scheme 4: Large-scale one-pot solvent-free synthesis of amides 6a,b from the corresponding propargylic alcoho...
Scheme 5: AlCl3-promoted hydroarylation of allene 1b by benzene leading to alkene Z-11n.
Scheme 6: Reaction of allene 1a with benzene under the action of AlCl3 followed by quenching of the reaction ...
Scheme 7: Multigram-scale one-pot synthesis of indane 12d from 2-methylbut-3-yn-2-ol.
Figure 3: NMR spectra of starting allene 1a (black) and its complex with 1 equivalent of AlCl3 13 (red) in CD2...
Scheme 8: 1H, 13C, and 31P NMR monitoring of AlCl3-promoted reactions of allene 1a leading to compounds E-14 ...
Scheme 9: Plausible reaction mechanism A for the formation of compounds 9, 10, 11, 12 from aillene 1a involvi...
Scheme 10: Plausible reaction mechanism B of formation of compounds 11, 12 from allene 1a involving HCl–AlCl3 ...
Figure 4: Visualization of LUMO, only positive values are shown, isosurface value 0.043: (a) species 16, (b) ...
Beilstein J. Org. Chem. 2019, 15, 1289–1297, doi:10.3762/bjoc.15.127
Graphical Abstract
Figure 1: Рharmacologically active sulfones.
Figure 2: Structures of the ligands L1–L8.
Figure 3: Evolution of the conversion of 5 and diastereomeric composition of the products of reaction of 5a w...
Figure 4: Time profile of epimerization and retro-Michael reaction of (2R,3S)-8a in chloroform-d solution.
Figure 5: ORTEP diagram of (2R,3S)-8d.
Scheme 1: The proposed mechanism of asymmetric addition of β-ketosulfones to nitroalkenes.
Scheme 2: Transition state models for asymmetric addition of β-ketosulfones to nitroalkenes.
Beilstein J. Org. Chem. 2019, 15, 1116–1128, doi:10.3762/bjoc.15.108
Graphical Abstract
Scheme 1: Comparison of Dmoc and dM-Dmoc as nucleobase protecting groups for ODN synthesis.
Figure 1: dM-Dmoc phosphoramidite monomers and CPG with Dmoc linker.
Scheme 2: Synthesis of compound 5 [44], nucleoside phosphoramidite monomers 3a–c and phosphoramidite capping agen...
Figure 2: Structure of phosphoramidites containing electrophilic groups.
Scheme 3: Synthesis of ester-containing phosphoramidite 26a.
Figure 3: ODN sequences 30a–e. Their 5'-tritylated versions are labeled as 30a-tr, 30b-tr, 30c-tr, 30d-tr, an...
Figure 4: RP HPLC profiles of (a) crude 30a-tr, (b) pure 30a-tr, (c) crude 30a, (d) pure 30a, (e) crude 30c-tr...
Figure 5: PAGE analyses of ODNs 30a–e. Lanes 1–5 are ODNs 30a–e, respectively.
Figure 6: MALDI–TOF MS of (a) ODN 30a and (b) 30c.
Scheme 4: ODN deprotection and cleavage under non-nucleophilic conditions.
Beilstein J. Org. Chem. 2019, 15, 1032–1045, doi:10.3762/bjoc.15.101
Graphical Abstract
Figure 1: 2-Aminoimidazole alkaloids from marine sponges.
Figure 2: The Knoevenagel–Michael adduct [24] and expected products.
Scheme 1: The three component condensation of imidazo[1,2-a]pyridine, aldehydes and Meldrum’s acid described ...
Figure 3: Molecular structure of 1-([1,1'-biphenyl]-4-yl)-5-oxo-7-phenyl-6,7-dihydro-5H-pyrrolo[1,2-c]imidazo...
Scheme 2: Two forms of cation 9i.
Figure 4: Molecular structure of 3-(2-amino-4-phenyl-1H-imidazol-5-yl)-3-(p-tolyl)propanoic acid 11b accordin...
Scheme 3: Three forms of the compound 11b in the crystal phase.
Scheme 4: Synthesis of the mixture of compounds 13 and 14.
Figure 5: Molecular structure of aminoimidazo[1,2-c]pyrrole 16a according to X-ray diffraction data. Thermal ...
Scheme 5: Resonance structures of 16a.
Figure 6: 3,3’-Spirooxindole alkaloids.
Figure 7: Molecular structure of aminoimidazo[1,2-c]pyrrole 19a according to X-ray diffraction data. Thermal ...
Scheme 6: Resonance structures of 19a.
Beilstein J. Org. Chem. 2019, 15, 769–779, doi:10.3762/bjoc.15.73
Graphical Abstract
Figure 1: Commercially available ruthenium catalysts for metathesis reactions.
Figure 2: Retrosynthesis of the ruthenium catalysts.
Scheme 1: Efficient multigram synthesis of N,N-dialkyl-2-vinylbenzylamines 4 (R1X = Me2SO4, Et2SO4 or BnCl, s...
Scheme 2: Synthesis of N-(2-ethenylbenzyl)heterocycles 5.
Scheme 3: Synthesis of N-monoalkyl-2-vinylbenzylamine 7.
Scheme 4: Synthesis of Hoveyda–Grubbs-type catalysts 11.
Scheme 5: Synthesis of the “chloroform adduct” 9.
Figure 3: Selected X-ray data for ruthenium complexes 11a–c. All hydrogen atoms were deleted for clarity (exc...
Scheme 6: Catalytic activity of compounds 11 in the metathesis reactions.
Beilstein J. Org. Chem. 2019, 15, 761–768, doi:10.3762/bjoc.15.72
Graphical Abstract
Figure 1: Structure of biaryl bicyclic peptides 1–3.
Scheme 1: Retrosynthetic analysis for the biaryl bicyclic peptide 1.
Scheme 2: Synthesis of the biaryl bicyclic peptide 1 incorporating a Phe-Phe linkage. Reagents and conditions...
Scheme 3: Synthesis of the biaryl bicyclic peptide 2 incorporating a Phe-Tyr linkage. Reagents and conditions...
Scheme 4: Synthesis of the biaryl bicyclic peptide 3 incorporating a Tyr-Tyr linkage. Reagents and conditions...
Beilstein J. Org. Chem. 2019, 15, 655–678, doi:10.3762/bjoc.15.61
Graphical Abstract
Scheme 1: Discovery of the LANCA three-component reaction. The reaction of pivalonitrile (1) with lithiated m...
Scheme 2: Proposed mechanism of the LANCA three-component reaction to β-ketoenamides KE and pyridin-4-ol deri...
Scheme 3: One-pot preparation of pyridin-4-ols PY and their subsequent transformations to highly substituted ...
Scheme 4: Synthesis of β-ketoenamides KE by the LANCA three-component reaction of alkoxyallenes, nitriles and...
Scheme 5: β-Ketoenamides KE36–43 derived from enantiopure components.
Scheme 6: Bis-β-ketoenamides KE44–46 derived from aromatic dicarboxylic acids.
Scheme 7: Conversion of alkyl propargyl ethers E into aryl-substituted β-ketoenamides KEAr and selected produ...
Scheme 8: Condensation of LANCA-derived β-ketoenamides KE with ammonium salts to give 5-alkoxy-substituted py...
Scheme 9: Synthesis of PM31–35 from β-ketoenamides KE37, KE38, KE40, KE41 and KE78 obtained by method A (NH4O...
Scheme 10: Synthesis of bis-pyrimidine derivatives PM36, PM39 and PM40 from β-ketoenamides KE44–46 by method A...
Scheme 11: Functionalization of pyrimidine derivatives PM through selenium dioxide oxidations of PM5, PM9, PM15...
Scheme 12: Conversion of 2-vinyl-substituted pyrimidine PM7 into aldehyde PM50; (NMO = N-methylmorpholine N-ox...
Scheme 13: Deprotection of 5-alkoxy-substituted pyrimidines PM2, PM20 and PM29 and conversion into nonaflates ...
Scheme 14: Palladium-catalyzed coupling reactions of PM54 and PM12 giving rise to new pyrimidine derivatives P...
Scheme 15: Synthesis of pyrimidyl-substituted pyridyl nonaflate PM60.
Scheme 16: Condensation of LANCA-derived β-ketoenamides KE with hydroxylamine hydrochloride leading to pyrimid...
Scheme 17: Reactions of β-ketoenamides KE15 and KE7 with hydroxylamine hydrochloride leading to pyrimidine N-o...
Scheme 18: Structures of pyrimidine N-oxides PO30–33 derived from β-ketoenamides KE43, KE45, KE78 and KE80.
Scheme 19: Reduction of PO4 to PM5 and Boekelheide rearrangements of PO13, PO14, PO4 and PO30 to 4-acetoxymeth...
Scheme 20: Deprotection of 4-acetoxymethyl-substituted pyrimidine derivatives PM61 and PM63, oxidations to for...
Scheme 21: Synthesis of pyrimidinyl-substituted alkyne PM74 and conversion into furopyrimidine PM75 and Sonoga...
Scheme 22: Trifluoroacetic acid-promoted conversion of LANCA-derived β-ketoenamides KE into oxazoles OX and 1,...
Scheme 23: Conversion of β-ketoenamide KE79 into oxazole OX16 and transformation into 5-styryl-substituted oxa...
Scheme 24: Mechanisms of the formation of 1,2-diketones DK and of acetyl-substituted oxazole derivatives OX.
Scheme 25: Hydrogenolyses of benzyloxy-substituted β-ketoenamides KE52 and KE54 to 1,2-diketone DK14 and to di...
Scheme 26: Conversions of 2,4-dicyclopropyl-substituted oxazole OX7 into oxazole derivatives OX18–20 (PPA = po...
Scheme 27: Syntheses of vinyl and ethynyl-substituted oxazole derivatives OX21 and OX23 and their palladium-ca...
Scheme 28: Synthesis of C3-symmetric oxazole derivative OX28 and the STM current image of its 1-phenyloctane s...
Scheme 29: Condensation of 1,2-diketones DK with o-phenylenediamine to quinoxalines QU1–7 (CAN = cerium ammoni...
Scheme 30: The LANCA three-component reaction leading to β-ketoenamides KE and the structure of functionalized...